AOD-9604

II. What is this compound?

AOD-9604 is a modified fragment of human growth hormone, not a secretagogue and not a full GH analogue. Native hGH residues 177–191 form a short C-terminal stretch linked to lipid handling in earlier structure–function work. AOD-9604 adds an N-terminal tyrosine, producing a 16-amino-acid hexadecapeptide (not a 15-mer). The common sequence listing is Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, with a molecular weight near 1815 Da.

That structural choice matters for readers comparing peptides. ** Sermorelin Sermorelin growth hormone-releasing hormone (GHRH) analog GHRH analog for endogenous growth hormone stimulation / CJC-1295 CJC-1295 growth hormone releasing hormone (GHRH) analogue Growth hormone-releasing hormone analogue / ipamorelin Ipamorelin growth hormone secretagogue (GHS) / selective ghrelin receptor agonist Selective growth hormone secretagogue act upstream on the GH axis (GHRH or ghrelin pathways). AOD-9604 was designed downstream of that idea — a fragment hypothesized to retain fat-metabolism activity while avoiding GH-like rises in IGF-1 and glucose disruption** reported with intact hormone [3] PMID: 11146367 [4] PMID: 11713213 .

Historically it was developed as an anti-obesity drug candidate (hence "Advanced Obesity Drug 9604"). That framing is useful for search and for honesty: this is a clinical-development story that stopped, not a new "miracle peptide" narrative. Research-use listings still appear in the gray market under fragment branding, which is exactly why accurate AA count, trial status, and citation hygiene matter on a science-first page.

If you only remember one structural fact: 16 residues (hexadecapeptide), Tyr-hGH 177–191, studied first in metabolic animal models, then in human oral/IV programs that never reached approval.

III. How it works

Two linked actions show up repeatedly in the AOD-9604 literature: more fat breakdown (lipolysis / fat oxidation) and less fat formation (anti-lipogenesis) in research models [5] PMID: 11146367 [6] PMID: 11713213 .

Early framing emphasized the β3-adrenergic receptor pathway — a receptor class involved in brown/beige fat thermogenesis and catecholamine-driven lipolysis in rodents. That hypothesis is still useful as a starting model, but it is incomplete. Heffernan and colleagues showed that AOD9604 still affected lipid metabolism in β3-adrenergic receptor knockout mice, which means the peptide's metabolic effects are not solely β3-dependent [7] PMID: 11713213 . Honest copy should say hypothesized or partial β3 involvement, plus other lipolytic / anti-lipogenic routes still being mapped.

A second differentiator versus intact hGH is the absence of the classic GH "growth" signature in the fragment literature: researchers reported lipid effects without the same impact on blood glucose or IGF-1 that complicates full-length hormone use [8] PMID: 11713213 [9] PMID: 11146367 . That separation is why AOD-9604 was attractive as a drug candidate — and why it is often contrasted with GH secretagogues that raise GH/IGF-1 on purpose.

Mechanistically, think of AOD-9604 as a focused lipid-metabolism fragment experiment, not a general GH replacement. Pathway language on this page stays evidence-hedged: animal data plus human exposure/safety history, not a settled exclusive β3 story.

• Stimulation of lipolysis / fat oxidation; β3-adrenergic involvement is hypothesized but not exclusive (effect retained in β3-AR knockout mice)
  PMID 11713213PMID 11146367
• Inhibition of lipogenesis without the classic GH effects on blood glucose or IGF-1 elevation seen with intact hGH
  PMID 11713213PMID 11146367

IV. Research Findings

Animal models are the strongest part of the efficacy narrative. Chronic treatment studies in obese mice reported favorable shifts in lipid metabolism with AOD9604, including work that compared the fragment with human GH and tested β3-AR knockout animals [10] PMID: 11713213 . Related metabolic studies of the synthetic lipolytic domain likewise framed AOD9604 as a tool to probe GH-fragment lipid effects [11] PMID: 11146367 . Those data support research interest in fat-mass and metabolic endpoints — they do not by themselves establish human weight-loss efficacy.

Human clinical development is more nuanced and must be told without spin. Multiple randomized, double-blind, placebo-controlled trials evaluated safety, tolerability, and body-weight endpoints with oral and intravenous regimens (program codes such as METAOD001–006 appear in the Stier et al. 2013 clinical safety synthesis). Across those trials, AOD9604's safety/tolerability profile was described as generally similar to placebo, without the adverse metabolic signature classically associated with intact hGH.

Efficacy, however, did not clear the bar for continued drug development. Earlier shorter studies were sometimes discussed as directionally interesting for weight change; the larger, longer Phase IIb OPTIONS-type programs failed to show statistically significant weight loss versus placebo at the oral doses tested, and Metabolic Pharmaceuticals halted AOD-9604 development around 2007. For readers: safety data is not a proven fat-loss drug.

Bottom line for research framing: preclinical lipid signals are real and citable; human Phase 1–2 exposure and safety summaries exist; pivotal efficacy did not support approval. Any fat-loss peptide marketing that skips the Phase IIb failure is incomplete.

• fat-loss mixed (animal positive; human Phase 2 efficacy inconsistent / pivotal Phase IIb failed primary endpoint)
  PMID 11713213PMID 11146367
• metabolic-health preclinical plus human safety-focused Phase 1–2 programs
  PMID 11713213PMID 11146367

V. Dosage Context Explained

Dosage language for AOD-9604 has to be split into three different worlds: animal experiments, historical human trial regimens, and anecdotal research-community protocols. Mixing them is how incorrect mcg/day claims get attached to the wrong papers.

Human oral development used milligram-scale daily capsules or tablets, not microgram injections as the primary Phase II design. Published program summaries describe multi-week oral dosing in obese adults — for example Phase IIb tablet arms around 0.25, 0.5, or 1 mg/day for 24 weeks (METAOD006 / OPTIONS-era work) and earlier capsule studies exploring broader oral ranges (including higher mg/day arms in intermediate studies). Early IV work used single µg/kg-scale doses (on the order of 25–100 µg/kg) for safety/pharmacology.

Animal studies (including Heffernan 2001 and Ng 2000) used species-specific chronic regimens to probe lipid metabolism; those protocols are not plug-and-play human doses [12] PMID: 11713213 [13] PMID: 11146367 .

Subcutaneous microgram protocols (often discussed online as roughly 250–500 mcg/day, sometimes 300–600 mcg/day) are anecdotal research-community patterns. They are not the primary endpoints of the oral Phase II obesity program and must not be cited as if they came from unrelated literature or as approved therapy. All figures on this page are research history / research context only — not medical advice, not a protocol prescription.

• Administration Routes

  oral

  Range

  0.25–1 mg/day tablets (METAOD006 Phase IIb); earlier capsules up to ~1–30 mg/day in Phase IIa/IIb programs

  Human clinical development (Metabolic Pharmaceuticals): multi-trial oral program summarized in Stier et al. 2013 (JOFEM). Pivotal 24-week OPTIONS Phase IIb failed primary weight-loss endpoint; development halted ~2007. Research history only — not medical advice.

• Administration Routes

  intravenous

  Range

  single doses ~25–100 µg/kg (early Phase I/IIa safety studies)

  Early human IV single-dose safety studies in obese volunteers (METAOD001–002 program summary).

• Administration Routes

  subcutaneous

  Range

  often discussed anecdotally as ~250–500 mcg/day (sometimes cited 300–600 mcg/day)

  Anecdotal research-community protocols — NOT primary RCT endpoints from the oral Phase II program. Do not present as study-backed human therapeutic dosing.

• Administration Routes

  subcutaneous / experimental (animal)

  Range

  species- and study-specific chronic regimens in obese mouse models

  Preclinical lipid-metabolism work including Heffernan et al. (obese mice and β3-AR KO mice) [PMID: 11713213] and related metabolic studies [PMID: 11146367].

  PMID 11713213PMID 11146367

VI. Side Effects: Research Context

The most systematic human safety picture comes from the six randomized, double-blind, placebo-controlled trials summarized by Stier and colleagues (2013): overall, AOD9604 was reported as well tolerated, with a profile described as indistinguishable from placebo in that synthesis, and without the classic adverse effects associated with intact hGH in the authors' framing.

That is encouraging for research risk discussion, but it is not a blank check. Trial populations, durations, and routes (IV bolus vs multi-week oral) differ from informal research use. Injection-site redness and transient headache appear in anecdotal subcutaneous research chatter; incidence rates from large modern pharmacovigilance databases are not what this page claims.

Contraindication-style caution still applies in research settings: pregnancy/breastfeeding and active malignancy are listed as avoid contexts on this site's compound schema, consistent with conservative peptide research practice. Anyone designing protocols needs institutional review, legal/regulatory compliance, and primary literature — not blog dosing folklore.

• in human RCTs: overall safety/tolerability reported similar to placebo (Stier et al. 2013 summary of six trials)
• transient headache (anecdotal research use)
• injection site redness (anecdotal subcutaneous research use)

VII. Frequently Asked Questions